Table 1.
Patient Characteristics.
| Variables | PD (N = 48) | PsPD (N = 30) | P-value | SNUH (N = 59) | SNUBH (N = 19) | P-value | Total (N = 78) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | ||||
| Age (median, range) | 55.5 (28–77) | 55.5 (22–75) | 0.95* | 56 (22–77) | 53 (28–75) | 0.77* | 55.5 (22–77) | ||||
| Gender | 0.03† | 0.18† | |||||||||
| Male | 27 | 56.3 | 24 | 80 | 41 | 69.5 | 10 | 52.6 | 51 | ||
| Female | 21 | 43.8 | 6 | 20 | 18 | 30.5 | 9 | 47.4 | 27 | ||
| MGMT promoter status | 0.28† | 0.61† | |||||||||
| Methylated | 18 | 37.5 | 15 | 50 | 24 | 40.7 | 9 | 47.4 | 33 | ||
| Unmethylated | 30 | 62.5 | 15 | 50 | 35 | 59.3 | 10 | 52.6 | 45 | ||
| IDH status | 0.73‡ | 0.04‡ | |||||||||
| Mutated | 1 | 2.1 | 2 | 6.7 | 3 | 5.1 | 0 | 0 | 3 | ||
| Wild-type | 43 | 89.6 | 26 | 86.7 | 54 | 91.5 | 15 | 78.9 | 69 | ||
| Unknown | 4 | 8.3 | 2 | 6.7 | 2 | 3.4 | 4 | 21.1 | 6 | ||
| Dose schedule of RT | 0.80‡ | 0.52‡ | |||||||||
| Hypofractionated | 4 | 8.3 | 2 | 6.7 | 5 | 8.5 | 1 | 5.3 | 6 | ||
| Conventional | 44 | 91.7 | 28 | 93.3 | 54 | 91.5 | 18 | 94.7 | 72 | ||
| CE lesion | 0.71† | ||||||||||
| PD | 37 | 62.7 | 11 | 57.9 | 48 | ||||||
| PsPD | 22 | 37.3 | 8 | 42.1 | 30 | ||||||
| Days to appear of CE lesion (median, range) |
123.5 (18–1251) | 82 (26–516) | 0.02* | 111 (22–1251) | 80 (18–464) | 0.91* | 104 (22–1251) | ||||
*Student’s T-test, †Chi-squared test, ‡Fisher’s exact test.
Abbreviations: PD, progressive disease; PsPD, pseudoprogression; MGMT, O6-methylguanine-DNA-methyltransferase; IDH, isocitrate dehydrogenase; CE, contrast enhancement; RT, radiation therapy; SNUH, Seoul National University Hospital; SNUBH, Seoul National University Bundang Hospital.